NASDAQ$LYEL
Lyell Immunopharma Inc · Q2 2025 earnings
Q2 2025 earnings · · After market close · Investor relations
Briefing
Lyell Immunopharma Inc reported a net loss of $42.7 million for the second quarter of 2025.
The company continued advancing its lead CAR T-cell therapy LYL314 in pivotal and Phase 1/2 trials for large B-cell lymphoma while managing operating expenses. Revenue remained minimal at $8 thousand, primarily from collaborations, with research and development expenses at $34.9 million. Cash position stood at $98.8 million, supporting ongoing clinical development.
- Net loss narrowed to $42.7 million from $45.8 million in Q2 2024, driven by lower R&D and G&A spend.
- LYL314 pivotal PiNACLE trial in 3L+ LBCL is underway with 17 U.S. sites enrolling; Phase 1/2 data showed high complete response rates.
- Cash and cash equivalents totaled $98.8 million as of June 30, 2025, with additional $50 million raised in July private placement.
- Company closed Los Angeles manufacturing facility after successful technology transfer to LyFE center in Bothell, WA.
Headline financials
Revenue & EPS history
Lyell Immunopharma · Revenue · Quarterly
$8K
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports
+1.5%
Avg return
Earnings day
-4.0%
Avg return
5 days after
+1.1%
Avg return
30 days after
73%
16 / 22 earnings
Positive
+20.3%
Q4 2024
Best reaction
-18.3%
Q3 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2025 | — | — | — | |
| Q1 2026 | +1.1% | -7.0% | -42.1% | |
| Q4 2025 | +2.5% | -19.0% | -9.6% | |
| Q3 2025 | -1.3% | +1.7% | +95.5% | |
| Q1 2025 | +4.6% | +2.0% | +21.1% | |
| Q4 2024 | +20.3% | +15.5% | -10.3% | |
| Q3 2024 | -17.6% | -21.3% | -38.9% | |
| Q2 2024 | +1.4% | -8.1% | -20.9% | |
| Q1 2024 | +7.6% | +4.2% | +13.6% | |
| Q4 2023 | +2.5% | -8.6% | -21.8% | |
| Q3 2023 | +6.8% | -24.8% | -11.8% | |
| Q2 2023 | +1.5% | -1.9% | -16.8% | |
| Q1 2023 | +6.9% | +6.5% | +50.9% | |
| Q4 2022 | +9.6% | +1.4% | -1.8% | |
| Q3 2022 | -18.3% | -17.0% | -28.8% | |
| Q2 2022 | +16.3% | +20.2% | +10.1% | |
| Q1 2022 | -12.4% | -22.8% | +1.5% | |
| Q1 2021 | -12.4% | -22.8% | +1.5% | |
| Q4 2019 | +6.1% | +6.1% | +1.6% | |
| Q4 2021 | +6.1% | +6.1% | +1.6% | |
| Q3 2021 | -4.1% | -3.6% | -18.8% | |
| Q2 2021 | +2.8% | +2.2% | +24.6% | |
| Q4 2020 | +2.8% | +2.2% | +24.6% | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro